Bristol Myers discloses patient death in early-stage autoimmune disease trial; shares fall

** Bristol Myers Squibb BMY.N shares fall 2.4% to $61.47

** Co says after the data cutoff of an early-stage trial, one patient experienced a fatal event of septic pneumonia

** Co was testing its experimental cancer therapy zolacabtagene autoleucel in patients with highly active relapsing multiple sclerosis

** Multiple sclerosis is an autoimmune disease that affects the central nervous system

** The trial included 66 patients and the therapy's safety profile was shown to be consistent with previously reported data, co says

** Including session moves, stock up 13.9% YTD